These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 15765009)

  • 61. Genetic variations in peroxisome proliferator-activated receptor gamma expression affect blood pressure.
    Tsai YS; Xu L; Smithies O; Maeda N
    Proc Natl Acad Sci U S A; 2009 Nov; 106(45):19084-9. PubMed ID: 19884495
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Inguinal Fat Compensates Whole Body Metabolic Functionality in Partially Lipodystrophic Mice with Reduced PPARγ Expression.
    Chang CS; Yu SS; Ho LC; Chao SH; Chou TY; Shao AN; Kao LZ; Chang CY; Chen YH; Wu MS; Tsai PJ; Maeda N; Tsai YS
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835312
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Familial partial lipodystrophy resulting from loss-of-function PPARγ pathogenic variants: phenotypic, clinical, and genetic features.
    Soares RMV; da Silva MA; Campos JTAM; Lima JG
    Front Endocrinol (Lausanne); 2024; 15():1394102. PubMed ID: 39398333
    [TBL] [Abstract][Full Text] [Related]  

  • 64. PPARγ and Diabetes: Beyond the Genome and Towards Personalized Medicine.
    Cataldi S; Costa V; Ciccodicola A; Aprile M
    Curr Diab Rep; 2021 Apr; 21(6):18. PubMed ID: 33866450
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Computational analysis of single nucleotide polymorphisms (SNPs) in PPAR gamma associated with obesity, diabetes and cancer.
    Stalin A; Lin D; Josephine Princy J; Feng Y; Xiang H; Ignacimuthu S; Chen Y
    J Biomol Struct Dyn; 2022 Mar; 40(4):1843-1857. PubMed ID: 33089758
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Interaction between Calpain 5, Peroxisome proliferator-activated receptor-gamma and Peroxisome proliferator-activated receptor-delta genes: a polygenic approach to obesity.
    Sáez ME; Grilo A; Morón FJ; Manzano L; Martínez-Larrad MT; González-Pérez A; Serrano-Hernando J; Ruiz A; Ramírez-Lorca R; Serrano-Ríos M
    Cardiovasc Diabetol; 2008 Jul; 7():23. PubMed ID: 18657264
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Non-DNA binding, dominant-negative, human PPARgamma mutations cause lipodystrophic insulin resistance.
    Agostini M; Schoenmakers E; Mitchell C; Szatmari I; Savage D; Smith A; Rajanayagam O; Semple R; Luan J; Bath L; Zalin A; Labib M; Kumar S; Simpson H; Blom D; Marais D; Schwabe J; Barroso I; Trembath R; Wareham N; Nagy L; Gurnell M; O'Rahilly S; Chatterjee K
    Cell Metab; 2006 Oct; 4(4):303-11. PubMed ID: 17011503
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Pathogenic genes and adipogenic differentiation transcription factor PPARγ associated with congenital lipodystrophic diabetes].
    Zhang X; Qin Y; Lin F
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2019 Aug; 36(8):844-847. PubMed ID: 31400143
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Prepubertal onset of type 2 diabetes in Shashi-Pena syndrome due to ASXL2 mutation.
    Murphy SA; O'Rourke NE; O'Grady MJ
    Am J Med Genet A; 2022 Sep; 188(9):2803-2807. PubMed ID: 35716351
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [The role of peroxisome proliferator activated receptors in metabolic balance disturbances under stress].
    Dushkin MI; Khrapova MV
    Usp Fiziol Nauk; 2011; 42(2):3-24. PubMed ID: 21735702
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Retinoid X receptor heterodimers in the metabolic syndrome.
    Hegele RA
    N Engl J Med; 2005 Nov; 353(19):2088. PubMed ID: 16282190
    [No Abstract]   [Full Text] [Related]  

  • 72. [Hypertension and metabolic syndrome/lifestyle diseases].
    Takeuchi K
    Rinsho Byori; 2007 May; 55(5):452-6. PubMed ID: 17593691
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Genetics of insulin resistance.
    Mercado MM; McLenithan JC; Silver KD; Shuldiner AR
    Curr Diab Rep; 2002 Feb; 2(1):83-95. PubMed ID: 12643127
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Abdominal subcutaneous adipose tissue morphology in a patient with a dominant-negative mutation (P467L) in the nuclear receptor peroxisome proliferator-activated receptor-gamma (PPARG) gene.
    Boiani R; Cinti S; Savage DB; Vidal-Puig A; O'Rahilly S
    Nutr Metab Cardiovasc Dis; 2010 Mar; 20(3):e11-2. PubMed ID: 20153617
    [No Abstract]   [Full Text] [Related]  

  • 75. Associations of Leptin Receptor and Peroxisome Proliferator-Activated Receptor Gamma Polymorphisms with Polycystic Ovary Syndrome.
    Joob B; Wiwanitkit V
    Ann Nutr Metab; 2019; 75(3):197. PubMed ID: 31618730
    [No Abstract]   [Full Text] [Related]  

  • 76. [Metabolic syndrome].
    Fukushima Y; Urakaze M; Tobe K
    Nihon Rinsho; 2010 Feb; 68(2):299-304. PubMed ID: 20158100
    [TBL] [Abstract][Full Text] [Related]  

  • 77. PPARγ Gene Polymorphisms, Metabolic Disorders, and Coronary Artery Disease.
    Song Y; Li S; He C
    Front Cardiovasc Med; 2022; 9():808929. PubMed ID: 35402540
    [TBL] [Abstract][Full Text] [Related]  

  • 78. PPAR Gamma: Coordinating Metabolic and Immune Contributions to Female Fertility.
    Minge CE; Robker RL; Norman RJ
    PPAR Res; 2008; 2008():243791. PubMed ID: 18309368
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A clinical link between peroxisome proliferator-activated receptor γ and the renin-angiotensin system.
    Sigmund CD
    Arterioscler Thromb Vasc Biol; 2013 Apr; 33(4):676-8. PubMed ID: 23486770
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Identification and Characteristics of Novel Mutations in Nonsyndromic Monogenic Obesity.
    Shi P; Shi Y; Liu X; Wang S; Yuan J; Zhao W; Fang L; Wang R; Yan F; Xu C
    Adv Biol (Weinh); 2023 Aug; 7(8):e2300061. PubMed ID: 37083215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.